Company
Life Biosciences
Scores have not been assigned.
Source Summary
1 reviewed source across 1 source category.
- Trial registries1
Company Snapshot
Event dates and registry update dates remain distinct.
Executive Summary
Life Biosciences sponsors ER-100, an investigational epigenetic-therapy study for optic-nerve conditions. The registered phase 1 trial, NCT07290244, concerns open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. It is an early clinical test of a defined intervention in specific patient groups.
Why It Matters
The reader can distinguish a registered disease-specific safety experiment from a proven rejuvenation treatment. This trial design supplies no basis for a human lifespan claim or a general safety assurance. Its value at this stage is the opportunity to test a hypothesis under an identifiable protocol, with results and limitations that can be examined as they become available.
Platform / Pipeline Overview
| Program | Mechanism / pathway | Stage / status | Source type | Evidence boundary | Caution note |
|---|---|---|---|---|---|
| ER-100 | Investigational epigenetic therapy | Registered phase 1 study | Sponsor-submitted trial registry | Open label, nonrandomized; estimated 18 participants; safety-oriented primary outcomes. | The May 2026 recruiting label does not confirm current enrollment. No posted registry results in the accepted record. |
Related Trials
| Registry ID | Status / phase | Relationship | What it supports | What it does not prove |
|---|---|---|---|---|
| NCT07290244 | Phase 1; recruiting label from 19 May 2026 update; no posted registry results | Life Biosciences Inc. is the sponsor of NCT07290244, a phase 1 ER-100 study in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The study is open label, nonrandomized and sequential, with an estimated 18 participants; the estimate is not an observed enrollment total. The registry describes ER-100 epigenetic therapy with doxycycline activation and monitoring during/after the activation period; its primary outcomes concern adverse events, dose-limiting toxicities and other safety assessments. As checked on 19 October 2026, the record lists recruiting in its latest posted update of 19 May 2026 and has no results posted. This does not establish the absence of company announcements or actual current enrollment. | The specific trial identity, design or dated status cited in this profile. | An uncontrolled early safety study cannot by itself establish that treatment causes visual improvement, resolves rare or delayed harms, or extends human lifespan. |
Timeline / Milestones
-
Latest posted registry update in the accepted evidence
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
As checked on 19 October 2026, the record lists recruiting in its latest posted update of 19 May 2026 and has no results posted. This does not establish the absence of company announcements or actual current enrollment.
Source Posture
Trial registries
Sponsor-submitted design/status metadata; posted or completed status does not establish efficacy.
Editorial interpretation
An uncontrolled early safety study cannot by itself establish that treatment causes visual improvement, resolves rare or delayed harms, or extends human lifespan.
Evidence / Claim Boundary
What the trial is designed to learn
The registry describes an open-label, nonrandomized study with sequential dose cohorts and an estimated 18 participants. Its primary outcomes focus on safety, including adverse events and dose-limiting toxicities during and after doxycycline activation of the therapy. The enrollment figure is a plan, not a confirmed count of treated people.
Where the public registry stands
Checked on 19 October 2026, the most recent posted registry update is dated 19 May 2026. It lists the study as recruiting and contains no posted results. That describes the registry record; it does not establish current enrollment or rule out observations reported elsewhere.
How to interpret early observations
Without a randomized, blinded comparator, changes in visual testing cannot by themselves establish a causal treatment effect. A small early cohort also cannot settle durability, delayed effects or uncommon harms. The next useful evidence is transparent participant follow-up, exposure and adverse-event reporting, followed by appropriately controlled evaluation of visual outcomes.
What This Does Not Prove
Evidence limits
An uncontrolled early safety study cannot by itself establish that treatment causes visual improvement, resolves rare or delayed harms, or extends human lifespan.
Detailed Sources
View detailed source table
Trial registries
| Source | Type | Supports | Limitation | Link |
|---|---|---|---|---|
| Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) | Sponsor-submitted trial registry | Exact trial design and dated registry status. 2026-05-19 | Sponsor-submitted design/status metadata; posted or completed status does not establish efficacy. | Original source |
Confidence / Methodology
Confidence
Bounded source-reviewed profile; independent specialist clearance is not implied.
Methodology note
Facts and registry labels checked as of 2026-10-19. Only the public trial registry supports this profile’s factual content. The registry label and update date are distinct from actual current enrollment. Editorial interpretation is distinct from a demonstrated treatment result.
Last reviewed
2026-10-19